In Situ Synthesis Of GPCR Ligands

GPCR 配体的原位合成

基本信息

  • 批准号:
    8620213
  • 负责人:
  • 金额:
    $ 20.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-03-01 至 2016-02-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): G-protein coupled receptors (GPCRs) constitute the largest family of membrane proteins in the human genome with approximately 800 members. GPCR signaling through multiple effector pathways has profound therapeutic implications, making these receptors the targets of ~40% of currently marketed drugs. Modulation of GPCR activity by small molecule ligands is emerging as a new strategy for development of anticancer therapeutics. However, design of new drugs with higher efficacy and lower side effects, and detailed understanding of GPCR mechanism of action are hampered by the limited structural information. Structural studies of many GPCRs are in turn limited by a scarcity of high-affinity ligands that stabilize GPCRs and enable their crystallization. The project attempts to develop a new platform using the in situ click chemistry approach to discover novel ligands that bind GPCRs to serve as tool compounds for structural and functional studies or as starting point for drug discovery. Target-guided synthesis approaches including in situ click chemistry, by which reactive fragments are joined in the binding sites of a biological target, have shown great promise in drug discovery but have not been applied to GPCRs. The challenges lie in the GPCRs' membrane disposition, their high conformational dynamics, low stability and low expression levels. The proposed platform is being developed targeting all GPCRs, with initial focus primarily on those known to be cancer targets. In the two years of this study, we will focus on smoothened (SMO) receptor which is an orphan receptor and a key signal transducer in the Hedgehog (Hh) signaling pathway activated during development, and thus is a target of a number of antitumor drugs in clinical trials. Our goal will be attained by achieving the following two aims: (1) Establish an in situ click chemistry platform to generate high-affinity GPCR ligands, (2) Characterize the interaction between selected ligands from Aim 1 and SMO by crystallography. The study will be supported by a team that had developed the GPCR Structure Determination Pipeline as well as its underlying technologies which have led to the structure determination of 12 GPCR structures since 2007.
描述(由申请人提供):G蛋白偶联受体(GPCR)是人类基因组中最大的膜蛋白家族,约有800个成员。通过多种效应子途径的GPCR信号传导具有深远的治疗意义,使这些受体成为目前市售药物的约40%的靶点。通过小分子配体调节GPCR活性正在成为开发抗癌治疗剂的新策略。然而,有限的结构信息阻碍了设计具有更高疗效和更低副作用的新药,以及详细了解GPCR的作用机制。许多GPCR的结构研究反过来又受到稳定GPCR并使其结晶的高亲和力配体的缺乏的限制。该项目试图使用原位点击化学方法开发一个新的平台,以发现结合GPCR的新型配体,作为结构和功能研究的工具化合物或作为药物发现的起点。包括原位点击化学在内的靶向合成方法,通过该方法将反应性片段连接到生物靶标的结合位点,在药物发现中显示出巨大的前景,但尚未应用于GPCR。挑战在于GPCR的膜处置、其高构象动力学、低稳定性和低表达水平。目前正在开发针对所有GPCR的拟议平台,最初主要关注已知的癌症靶点。在本研究的两年中,我们将重点关注smoothened(SMO)受体,它是一种孤儿受体,也是开发过程中激活的Hedgehog(Hh)信号通路中的关键信号转导子,因此是许多抗肿瘤药物在临床试验中的靶点。我们的目标是实现以下两个目标:(1)建立一个原位点击化学平台,以产生高亲和力的GPCR配体;(2)通过晶体学表征从Aim 1中选择的配体与SMO之间的相互作用。该研究将得到一个团队的支持,该团队开发了气相化学还原结构测定管道及其基础技术,自2007年以来,这些技术已导致对12种气相化学还原结构进行了结构测定。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Vadim Cherezov其他文献

Vadim Cherezov的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Vadim Cherezov', 18)}}的其他基金

Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief
用于缓解神经性疼痛的非成瘾性血管紧张素 AT2 抑制剂
  • 批准号:
    10396694
  • 财政年份:
    2020
  • 资助金额:
    $ 20.61万
  • 项目类别:
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief
用于缓解神经性疼痛的非成瘾性血管紧张素 AT2 抑制剂
  • 批准号:
    10405661
  • 财政年份:
    2020
  • 资助金额:
    $ 20.61万
  • 项目类别:
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief
用于缓解神经性疼痛的非成瘾性血管紧张素 AT2 抑制剂
  • 批准号:
    10645104
  • 财政年份:
    2020
  • 资助金额:
    $ 20.61万
  • 项目类别:
Structural biology of G protein-coupled receptors
G蛋白偶联受体的结构生物学
  • 批准号:
    9925243
  • 财政年份:
    2018
  • 资助金额:
    $ 20.61万
  • 项目类别:
Structural biology of G protein-coupled receptors
G蛋白偶联受体的结构生物学
  • 批准号:
    10396469
  • 财政年份:
    2018
  • 资助金额:
    $ 20.61万
  • 项目类别:
Structure guided design of photoselectable channelrhodopsins
光选择性通道视紫红质的结构引导设计
  • 批准号:
    9244699
  • 财政年份:
    2016
  • 资助金额:
    $ 20.61万
  • 项目类别:
Structure guided design of photoselectable channelrhodopsins
光选择性通道视紫红质的结构引导设计
  • 批准号:
    9360611
  • 财政年份:
    2016
  • 资助金额:
    $ 20.61万
  • 项目类别:
HT structure determination of GPCRs by LCP serial femtosecond nanocrystallography
LCP 系列飞秒纳米晶体学测定 GPCR 的 HT 结构
  • 批准号:
    9078982
  • 财政年份:
    2014
  • 资助金额:
    $ 20.61万
  • 项目类别:
In Situ Synthesis Of GPCR Ligands
GPCR 配体的原位合成
  • 批准号:
    8788814
  • 财政年份:
    2014
  • 资助金额:
    $ 20.61万
  • 项目类别:
HT structure determination of GPCRs by LCP serial femtosecond nanocrystallography
LCP 系列飞秒纳米晶体学测定 GPCR 的 HT 结构
  • 批准号:
    8612932
  • 财政年份:
    2014
  • 资助金额:
    $ 20.61万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 20.61万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 20.61万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 20.61万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 20.61万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了